{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:46:19Z","timestamp":1771256779287,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clgc.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T03:24:53Z","timestamp":1542857093000},"page":"e258-e262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Jacopo","family":"Giuliani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.11.010_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2006.07.8956","article-title":"European perspective on the costs and cost-effectiveness of cancer therapies","volume":"25","author":"Drummond","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0973-1482.39685","article-title":"Criteria for deciding cost-effectiveness for expensive anti-cancer agents","volume":"4","author":"Sarin","year":"2008","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.clgc.2018.11.010_bib3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejca.2014.02.007","article-title":"Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy","volume":"50","author":"Calvo","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.11.010_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.11.010_bib5","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.11.010_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib7","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib8","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/annonc\/mdw258","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib9","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.11.010_bib10","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.11.010_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib12","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1016\/j.clgc.2018.02.006","article-title":"Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma","volume":"16","author":"Giuliani","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.11.010_bib13","first-page":"335","article-title":"The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma","volume":"24","author":"Swallow","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clgc.2018.11.010_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/CEOR.S159833","article-title":"Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England","volume":"10","author":"Meng","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clgc.2018.11.010_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14737167.2015.1102633","article-title":"The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology","volume":"15","author":"Olchanski","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clgc.2018.11.010_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2014.56.5887","volume":"33","author":"Shi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3892\/mco.2014.323","article-title":"Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: a network meta-analysis of randomised clinical trials","volume":"2","author":"Leung","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00432-013-1510-5","article-title":"Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy","volume":"139","author":"Dranitsaris","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2018.11.010_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1046\/j.1525-1497.1998.00201.x","article-title":"The effectiveness of cost-effectiveness analysis in containing costs","volume":"13","author":"Azimi","year":"1998","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.clgc.2018.11.010_bib21","doi-asserted-by":"crossref","first-page":"e011965","DOI":"10.1136\/bmjopen-2016-011965","article-title":"Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis","volume":"7","author":"Hill","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.clgc.2018.11.010_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22060","article-title":"Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation","volume":"22","author":"Edwards","year":"2018","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clgc.2018.11.010_bib23","first-page":"335","article-title":"The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma","volume":"24","author":"Fishman","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:48Z","timestamp":1761564648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318306748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1558767318306748"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.11.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}